Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.54 in the prior trading day, Autolus Therapeutics plc ADR (NASDAQ: AUTL) closed at $1.46, down -5.19%. In other words, the price has decreased by -$5.19 from its previous closing price. On the day, 2.16 million shares were traded. AUTL stock price reached its highest trading level at $1.56 during the session, while it also had its lowest trading level at $1.46.
Ratios:
Our goal is to gain a better understanding of AUTL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.03 and its Current Ratio is at 8.38. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Goldman on November 18, 2024, Upgraded its rating to Buy and sets its target price to $7.60 from $7 previously.
On November 15, 2024, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $13.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $10.Deutsche Bank initiated its Buy rating on November 09, 2023, with a $10 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUTL now has a Market Capitalization of 388566464 and an Enterprise Value of 243453456. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.87 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 8.133 whereas that against EBITDA is -0.932.
Stock Price History:
The Beta on a monthly basis for AUTL is 1.83, which has changed by -0.56676555 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, AUTL has reached a high of $4.59, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -5.17%, while the 200-Day Moving Average is calculated to be -20.18%.
Shares Statistics:
The stock has traded on average 3.67M shares per day over the past 3-months and 2315650 shares per day over the last 10 days, according to various share statistics. A total of 266.14M shares are outstanding, with a floating share count of 240.33M. Insiders hold about 9.70% of the company’s shares, while institutions hold 58.88% stake in the company. Shares short for AUTL as of 1760486400 were 11821704 with a Short Ratio of 3.22, compared to 1757894400 on 10606444. Therefore, it implies a Short% of Shares Outstanding of 11821704 and a Short% of Float of 5.8500000000000005.
Earnings Estimates
Autolus Therapeutics plc ADR (AUTL) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.13 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.52 and -$1.1 for the fiscal current year, implying an average EPS of -$0.83. EPS for the following year is -$0.63, with 7.0 analysts recommending between -$0.35 and -$1.01.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $26.51M. There is a high estimate of $37.11M for the next quarter, whereas the lowest estimate is $12.97M.
A total of 9 analysts have provided revenue estimates for AUTL’s current fiscal year. The highest revenue estimate was $97.13M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $73.1M. In the same quarter a year ago, actual revenue was $10.12MBased on 9 analysts’ estimates, the company’s revenue will be $138.96M in the next fiscal year. The high estimate is $293.45M and the low estimate is $57.19M.
